Although associated with more limitations, tumour-based molecular screening, e.g. by immunohistochemistry analysis of MMR protein expression [65] and analyses of tumour mutation burden and mutational signatures [61, 66], could also be used to identify CMMRD patients in relevant patient cohorts. The gene discussed is MRC1; the disease is neoplasm.